Institutions · Entity Annotation Prototype (beta)

1articles mentioning institutions

1institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: PARI Pharma GmbH ×

PARI Pharma GmbH

This institution is selected. Its supporting articles are shown below.

PARI Pharma GmbH1

Articles mentioning PARI Pharma GmbH

1 articles · page 1 of 1

Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis

bmjresp · abstract · 2025-12-25 · 1 matching annotations

89.6%

PARI Pharma GmbH pulmonary fibrosis pirfenidone AP01 interstitial lung diseases (ILDs)PPF NCT06329401

…al inhalation using the investigational eFlow Nebuliser System (PARI Pharma GmbH, Germany). The primary endpoint is the change from baseline in …

Browse institutions

PARI Pharma GmbH

Articles mentioning PARI Pharma GmbH

Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis